RxDoctor Payments Data

Jessica McCue, NP

Adult Health · Greensboro, NCNPI 1194294769

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.8% of the total across 405 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 58 manufacturers, the largest accounting for just 11.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,431, 4.4 times the $557 reported in 2021. Among adult health clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,923in general payments, 2019–2025

Across 405 payments — averaging $19.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$921
  • UCB, Inc.$763
  • Novartis$469
  • AstraZeneca$404
  • Jazz Pharmaceuticals Inc.$355
  • Merz Pharmaceuticals, LLC$310
  • plus $5K from 52 others

What the payments were for

  • Speaking & faculty fees$160%
  • Food & beverage$7,907100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie80$921
UCB, Inc.29$763
Novartis24$469
AstraZeneca(2 entities)14$404
Jazz Pharmaceuticals Inc.17$355
Merz Pharmaceuticals, LLC14$310
Biogen15$301
SK Life Science, Inc.10$221
Lundbeck LLC10$209
Neurocrine Biosciences, Inc.10$205
CSL Behring9$201
Takeda Pharmaceuticals U.S.A., Inc.7$180
Argenx US, Inc.10$178
Mallinckrodt Hospital Products Inc.8$177
Harmony Biosciences LLC3$168
Otsuka America Pharmaceutical, Inc.7$159
Neurelis, Inc.9$157
Amgen8$154
Lilly USA, LLC9$153
Axsome Therapeutics, Inc.7$134
Fresenius Kabi USA, LLC1$133
TG Therapeutics, Inc.5$128
Pfizer8$128
Sanofi5$124
EMD Serono, Inc.5$117
Genentech USA, Inc.5$111
Bristol Myers Squibb5$104
Acadia Pharmaceuticals Inc6$95
Amneal Pharmaceuticals LLC4$88
Teva Pharmaceuticals USA, Inc.5$85
Eisai Inc.5$81
Acorda Therapeutics, Inc5$79
GRT US Holding, Inc.3$68
Vanda Pharmaceuticals Inc.3$68
Collegium Pharmaceutical, Inc.3$53
ANI Pharmaceuticals, Inc.3$52
Corium, LLC3$50
Avion Pharmaceuticals3$47
Banner Life Sciences, LLC2$41
Scilex Pharmaceuticals Inc.2$36
Boston Scientific2$32
Greenwich Biosciences, Inc.2$31
Impel Pharmaceuticals Inc.2$31
Alnylam Pharmaceuticals Inc.2$31
Avadel CNS Pharmaceuticals, LLC2$30
Johnson & Johnson(2 entities)2$30
Ultragenyx Pharmaceutical Inc.1$28
Biohaven Pharmaceuticals, Inc.1$27
Microtransponder, Inc.1$21
Catalyst Pharmaceuticals, Inc.1$20
Kyowa Kirin, Inc.1$20
Biohaven Pharmaceutical Holding Company Ltd.1$19
Medtronic1$19
Arbor Pharmaceuticals, Inc.1$19
Upsher-smith Laboratories LLC1$17
Sandoz1$17
Aprecia Pharmaceuticals, LLC1$16
Sunovion Pharmaceuticals Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,923 in reported general payments places this provider in the 90th percentile of 614 adult health providers in North Carolina.

See all adult health providers in North Carolina

Medicare billing

Part B allowed, 2024
$35,053
Medicare patients
168
Services billed
2,292

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate41$69,364
UbrelvyUbrogepant28$34,557
QuliptaAtogepant29$31,065
Emgality PenGalcanezumab-Gnlm42$29,431
Aimovig AutoinjectorErenumab-Aooe13$19,520
VimpatLacosamide12$11,714
Ajovy AutoinjectorFremanezumab-Vfrm15$10,822
Levetiracetam197$5,610
Memantine Hcl164$3,973
Levetiracetam ErLevetiracetam73$3,153
Carbidopa-LevodopaCarbidopa/Levodopa92$2,760
Gabapentin201$2,241
Carbidopa-Levodopa ErCarbidopa/Levodopa32$2,188
Lacosamide19$1,445
Carbamazepine ErCarbamazepine14$1,336

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$128$69,36441 claims
AbbVieUbrelvy, Qulipta$921$65,62257 claims
UCB, Inc.Vimpat$763$11,71412 claims
Upsher-smith Laboratories LLCTopiramate$17$917136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 614 adult health providers in North Carolina.

Other adult health in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →